Amgen prepares for pricing battle over PCSK9-inhibitor Repatha; Otsuka loses Abilify lawsuit; healthcare and pharma marketers will boost spending on digital advertising in 2015
Teva reached a settlement with the Federal Trade Commission to resolve an antitrust suit that charged the drugmaker's subsidiary Cephalon with illegally blocking generic competition for narcolepsy drug Provigil.
The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate
The updated app now tracks everyday health metrics including weight, activity and glucose levels.
The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.
The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.
Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.
Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill
Twenty states now allow nurse practitioners to practice without an MD affiliation.
A horse race between Merck and Bristol-Myers Squibb, and the importance of one biomarker, will be a focus at the American Society of Clinical Oncology's annual meeting.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.